c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson’s Disease
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson’s Disease
Authors
Keywords
-
Journal
Frontiers in Aging Neuroscience
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2016-10-26
DOI
10.3389/fnagi.2016.00254
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
- (2016) Daniel J Klionsky et al. Autophagy
- Does ponatinib cross the blood-brain barrier?
- (2016) Muhammad B. Abid et al. BRITISH JOURNAL OF HAEMATOLOGY
- Activation of tyrosine kinase c-Abl contributes to α-synuclein–induced neurodegeneration
- (2016) Saurav Brahmachari et al. JOURNAL OF CLINICAL INVESTIGATION
- Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer
- (2016) Timothy P. Heffron JOURNAL OF MEDICINAL CHEMISTRY
- Synucleinopathies: past, present and future
- (2016) M. G. Spillantini et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Nilotinib – Differentiating the Hope from the Hype
- (2016) Richard K. Wyse et al. Journal of Parkinsons Disease
- Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
- (2016) Fernando Pagan et al. Journal of Parkinsons Disease
- The genetics of Parkinson's disease
- (2015) Stephen Mullin et al. BRITISH MEDICAL BULLETIN
- Current disease modifying approaches to treat Parkinson’s disease
- (2015) Dan Lindholm et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
- (2015) LANCET NEUROLOGY
- Basic science breaks through: New therapeutic advances in Parkinson's disease
- (2015) Patrik Brundin et al. MOVEMENT DISORDERS
- Disease-modifying strategies for Parkinson's disease
- (2015) Lorraine V. Kalia et al. MOVEMENT DISORDERS
- Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer’s disease models
- (2015) I. Lonskaya et al. NEUROSCIENCE
- Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
- (2015) Iciar Aviles-Olmos et al. Journal of Parkinsons Disease
- c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease
- (2014) Anne-Laure Mahul-Mellier et al. HUMAN MOLECULAR GENETICS
- CDK5-mediated phosphorylation and autophagy of RKIP regulate neuronal death in Parkinson's disease
- (2014) Zheng Wen et al. NEUROBIOLOGY OF AGING
- A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson’s disease
- (2014) Akie Tanabe et al. Frontiers in Cellular Neuroscience
- The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease
- (2014) Senthilkumar S. Karuppagounder et al. Scientific Reports
- Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of -synuclein in Parkinson's disease models
- (2013) M. L. Hebron et al. HUMAN MOLECULAR GENETICS
- Parkin Plays a Role in Sporadic Parkinson's Disease
- (2013) Ted M. Dawson et al. Neurodegenerative Diseases
- Neuroprotective Efficacy of a New Brain-Penetrating C-Abl Inhibitor in a Murine Parkinson’s Disease Model
- (2013) Syed Z. Imam et al. PLoS One
- Dopamine signaling negatively regulates striatal phosphorylation of Cdk5 at tyrosine 15 in mice
- (2013) Yukio Yamamura et al. Frontiers in Cellular Neuroscience
- Diabetes drugs and neurological disorders: new views and therapeutic possibilities
- (2013) Cesare Patrone et al. Lancet Diabetes & Endocrinology
- An update on dual Src/Abl inhibitors
- (2012) Francesca Musumeci et al. Future Medicinal Chemistry
- The Parkinson disease protein α-synuclein inhibits autophagy
- (2011) Ashley R. Winslow et al. Autophagy
- PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
- (2011) Joo-Ho Shin et al. CELL
- Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease
- (2011) Giuseppa Mudò et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Involvement of cyclin-dependent kinase-5 in the kainic acid-mediated degeneration of glutamatergic synapses in the rat hippocampus
- (2011) Noora Putkonen et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- c-Abl in Neurodegenerative Disease
- (2011) Sarah D. Schlatterer et al. JOURNAL OF MOLECULAR NEUROSCIENCE
- Novel Regulation of Parkin Function through c-Abl-Mediated Tyrosine Phosphorylation: Implications for Parkinson's Disease
- (2011) S. Z. Imam et al. JOURNAL OF NEUROSCIENCE
- What causes cell death in Parkinson's disease?
- (2010) Amitabh Gupta et al. ANNALS OF NEUROLOGY
- Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant
- (2010) Wei-Sheng Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Parkinson's disease: 10 years of progress, 1997-2007
- (2010) Stanley Fahn MOVEMENT DISORDERS
- Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function
- (2010) H. S. Ko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular biology of bcr-abl1-positive chronic myeloid leukemia
- (2008) A. Quintas-Cardama et al. BLOOD
- Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
- (2008) K. Porkka et al. BLOOD
- Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis
- (2008) Neil P. Shah et al. CANCER CELL
- Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
- (2008) L L Remsing Rix et al. LEUKEMIA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now